RCT | Efficacy and safety of Abrocitinib vs. Dupilumab in adults with moderate-to-severe atopic dermatitis.
25 Jul, 2022 | 12:44h | UTCEfficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial – The Lancet (link to abstract – $ for full-text)
Related: Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis – New England Journal of Medicine